Conference Description

Registration closed for this course!>p> April 26, 2008
Westin, St. Louis
811 Spruce Street
St. Louis, Missouri
(314) 621-2000

Tell a friend about this conference

Download the brochure for this conference

Release Date: April 26, 2008

Expiration Date: April 26, 2008

Estimated Time To Complete CME Activity: 7.0 Hours

Medium/Method: Live Conference

Hardware/Software Requirements: None

CME Credits: 12.75*

Nonrefundable registration fee: $0.

Target Audience: Physicians, Nurse Practitioners, and Physician Assistants.

Program Summary:
This educational activity is designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about TIA and CVA risk reduction, Restless Leg Syndrome, Chronic Insomnia, Incretins and Incretin-Mimetics and Insulin Therapy in Diabetes, Rheumatoid Arthritis, Fibromyalgia, and Chronic Pain Management. In planning this CME activity, the National Association for Continuing Education (NACE) performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Learning objectives (see below), linked to identified gaps, were developed and will be addressed by each presenter. This multidisciplinary program will utilize a variety of educational techniques incorporating the various aspects of Adult Learning Principles. There will be emphasis on audience participation utilizing interactive case-based presentations to deliver educational material. Participants will be asked to engage in pre and post testing to collect data for outcome studies and to uncover unmet needs for future programming. Each participant will be provided with a syllabus containing presentations, clinical tools, and practical guidelines at the start of the program to be used for future reference.

Learning Objectives:
At the conclusion of this program, participants should be able to:

1. list the four cardinal features of RLS; Name the category of pharmaceutical agents which is first line treatment for RLS; Define and treat augmentation
2. recognize the significant impact of insomnia in patients with co-morbid conditions; Increase awareness of behavioral and cognitive therapies; More effectively incorporate appropriate pharmacotherapeutic management to decrease morbidity and enhance quality of life
3. discuss new treatments for type 2 Diabetes including incretin-mimetics, DPP-IV inhibitors, and incretin analogs; Compare and contrast newer therapies with traditional antidiabetic agents; Discuss the place of newer agents in the overall management strategy for patients with Diabetes
4. explain the natural progression to relative insulin deficiency in patients with type 2 Diabetes; Recognize when to initiate insulin therapy and how to overcome barriers to do so; Identify methods of optimizing glycemic control in patients with type 2 Diabetes with the use of insulin; Explain risks and discuss approaches for minimizing risk of hypoglycemia and weight gain
5. More readily identify an acute ischemic stroke; Utilize current management strategies to improve outcomes; Recognize the most effective treatments for secondary prevention
6. Utilize a pain assessment tool for initial assessment and chronic monitoring during pain management; Choose stratified pharmacotherapy for diabetic peripheral neuropathic pain, osteoarthritis pain and low back pain
7. recognize criteria for accurate diagnosis of fibromyalgia established by the American College of Rheumatology; Describe patient demographics and associated features in fibromyalgia; Describe differential diagnosis and basic testing to aid in excluding other conditions; Understand the role of non-pharma cologic and pharma cologic treatment options; Recognize the role of analgesics like tramadol, and non-opioid pain modulating agents such as pramipexole, pregabalin, and duloxetine; Describe emerging therapeutic options on the horizon for fibromyalgia
8. define criteria for the diagnosis of RA; Outline potential benefits of early diagnosis and aggressive management; Describe why the TNF inhibitors and newer biologics can potentially improve outcomes and summarize their efficacy and safety

Agenda:

7:20-7:50 am		Continental Breakfast and Registration
7:50-8:10		Welcome Remarks Gregg Sherman, MD
8:10-9:10		Restless Leg Syndrome: Optimizing Treatment from a Patient Centered Approach Phyllis Zee, MD
9:10-10:00		Chronic Insomnia in Co-Morbid States Phyllis Zee, MD
10:00-10:20		Break/Vendor Area
10:20-11:10		Incretins and Incretin-Mimetics: The Role in Diabetes Christopher Newton, MD
11:10-12:10		Diabetes Mellitus - Case Studies in Insulin Therapy Christopher Newton, MD
12:10-1:00		Lunch
1:00-2:00		TIA and CVA - Risk Reduction and Prevention Evan Allen, MD
2:00-3:00		Case Studies in Chronic Pain Management Louis Kuritzky, MD
3:00-3:20		Break
3:20-4:10		Understanding Fibromyalgia - Biology and Therapy Yvonne Sherrer, MD
4:10-5:00		Rheumatoid Arthritis - Early Diagnosis and Effective Management Yvonne Sherrer, MD

Faculty:
Evan Allen, MD, MBA
Clinical Assistant Professor
Florida State University College of Medicine
Tallahassee, FL

Louis Kuritzky, MD
Clinical Assistant Professor
Department of Community Health & Family Medicine
University of Florida, Gainesville
Gainesville, FL

Christopher Alan Newton, MD
Division of Endocrinology
Department of Internal Medicine
Emory University School of Medicine
Atlanta, GA

Yvonne Sherrer, MD
Medical Director/Director of Clinical Research
Center for Rheumatology, Immunology and Arthritis
Fort Lauderdale, FL

Phyllis Zee, MD
Professor of Neurology and Neurobiology and Physiology
Northwestern University
Chicago, IL

Program Chair: Gregg Sherman, MD

Activity Director: Michelle Frisch, MPH

*Continuing Education Information
This activity has been reviewed and is acceptable for up to 12.75 Prescribed credit(s) by the American Academy of Family Physicians. Of these credits, 5.5 conform to the AAFP criteria for evidence-based CME clinical content. CME credit has been increased to reflect 2 for 1 credit for only the EB CME portion. When reporting AAFP credit, report total Prescribed and Elective credit for this activity. It is not necessary to label credit as evidence-based CME for reporting purposes.

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Massachusetts Medical School designates this educational activity for a maximum of 7.5 AMA PRA Category I Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 8.8 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity.

Policy on Faculty and Provider Disclosure: It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

This activity is supported by educational donations provided by: Amgen and Wyeth Pharmaceuticals, Amylin, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Endo, Lilly, Novo nordisk, sanofi-aventis, Sepracor, UCB.